Abivax SA (ABVX), a clinical-stage biotechnology company, has several anticipated milestones related to its lead drug candidate Obefazimod to watch for in the coming months.
Obefazimod, an orally administered small molecule that is designed to enhance the expression of miR-124 to stabilize the immune response, is being developed for the treatment of Inflammatory Bowel Disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com